Among severe side effects and PPAR-γ agonists, rosiglitazone has been associated with increased risks of cardiovascular events, while pioglitazone with significantly increased incidence of bladder cancer (Nissen and Wolski, 2007; Friedland et al., 2012). Here, PPARG is linked to urinary bladder carcinoma.